Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund

Fineline Cube Nov 14, 2024

Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...

Company Drug

Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment

Fineline Cube Nov 14, 2024

The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC

Fineline Cube Nov 14, 2024

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...

Company Deals

Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research

Fineline Cube Nov 14, 2024

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...

Company Deals

BioNTech Seals Acquisition of China’s Biotheus for Up to $950M

Fineline Cube Nov 14, 2024

China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...

Company Deals

Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China

Fineline Cube Nov 14, 2024

China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...

Company

Pfizer Considers Sale of Hospital Unit Amid Pressure from Starboard Value

Fineline Cube Nov 14, 2024

Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital,...

Company

FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo

Fineline Cube Nov 13, 2024

US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing...

Company

AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials

Fineline Cube Nov 13, 2024

UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the...

Company

BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra

Fineline Cube Nov 13, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...

Company

Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals

Fineline Cube Nov 13, 2024

Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6%...

Company Deals

Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881

Fineline Cube Nov 13, 2024

China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has...

Company Deals

Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange

Fineline Cube Nov 13, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin...

Company Deals

Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research

Fineline Cube Nov 13, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...

Company Medical Device

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials

Fineline Cube Nov 13, 2024

US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...

Company

Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra

Fineline Cube Nov 13, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial...

Company

Legend Biotech’s Q3 Revenue Soars 67% YOY Driven by Carvykti Sales

Fineline Cube Nov 13, 2024

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced its financial results for the third quarter...

Company Deals

Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia

Fineline Cube Nov 13, 2024

Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...

Company Deals

Vesalius Therapeutics Partners with GSK for Novel Parkinson’s Disease Treatments

Fineline Cube Nov 13, 2024

US-based Vesalius Therapeutics has entered into a strategic agreement with UK pharmaceutical giant GSK plc...

Company Deals

Flare Therapeutics and Roche Enter Strategic Collaboration for Oncology Drug Discovery

Fineline Cube Nov 13, 2024

US-based Flare Therapeutics Inc., a clinical-stage biotech company specializing in cancer therapies through the use...

Posts pagination

1 … 321 322 323 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.